GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

In October, GSK raised £885.6 million (around $1.08 billion) by selling some of its shares in Haleon, reducing its stake in the consumer-healthcare business to around 7.4%.

Shares in GSK lost 8% of their value today in the wake of the analyst comments, while Sanofi fell 3% and Haleon was down 6%, collectively wiping tens of billions of dollars off their valuations.

LONDON: In a long scripted overhaul of its business, British drugmaker GSK spun off its consumer health business in the biggest listing in Europe for more than a decade. The new company ...

Under pressure from activist investor Elliot Capital Management, GSK divested its consumer health business into a new entity, Haleon (HLN), which began trading in July 2022. Haleon stock is up 20% ...

GSK has dumped £978million of Haleon shares, cutting its stake in the world's largest standalone consumer healthcare firm to just 4.2 per cent. The FTSE 100 drugmaker revealed on Wednesday it had ...

GSK divested its consumer group (called Haleon) in July 2022. Given the strong valuations of consumer healthcare companies, we expect this unit will yield a stronger valuation than what is implied ...

Unrestricted access to all Essential and Insights content Access to the PRWeek Consultancy Tracker and the Top 150 Monthly Trading Tracker Hub In-depth reports including quarterly and annual ...